Tyrosine Kinase/Adaptateurs
Les inhibiteurs des tyrosines kinases et des adaptateurs sont des composés qui ciblent les tyrosines kinases et leurs protéines adaptatrices associées, jouant des rôles essentiels dans la signalisation cellulaire, la croissance et la différenciation. Ces inhibiteurs sont des outils essentiels dans la recherche sur le cancer, car de nombreuses tyrosines kinases sont impliquées dans les voies de signalisation qui favorisent la croissance tumorale et les métastases. En inhibant les tyrosines kinases, ces composés peuvent bloquer des cascades de signalisation cruciales, offrant ainsi des stratégies thérapeutiques potentielles pour divers cancers et autres maladies impliquant une signalisation cellulaire anormale. Chez CymitQuimica, nous offrons une gamme complète d'inhibiteurs de tyrosines kinases et d'adaptateurs de haute qualité pour soutenir vos recherches en oncologie, biologie moléculaire et développement de thérapies ciblées.
Sous-catégories appartenant à la catégorie "Tyrosine Kinase/Adaptateurs"
- ALK(112 produits)
- CSF-1R(42 produits)
- EGFR(572 produits)
- Récepteur Ephrin(23 produits)
- FLT(92 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(169 produits)
- SON(5 produits)
- Hck(3 produits)
- IGF-1R(88 produits)
- PDGFR(126 produits)
- PYK2(7 produits)
- Src(79 produits)
- Récepteur TAM(32 produits)
- Tie-2(20 produits)
- Récepteur Trk(59 produits)
- Tyrosine Kinases(26 produits)
- VEGFR(268 produits)
- c-Fms(108 produits)
- c-Kit(101 produits)
- c-Met/HGFR(128 produits)
- c-RET(51 produits)
Affichez 13 plus de sous-catégories
1370 produits trouvés pour "Tyrosine Kinase/Adaptateurs"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
TRK-IN-24
CAS :<p>TRK-IN-24 (compound 10g) is a selective inhibitor of Trk receptors, effectively targeting TRKA, TRKC, and mutant forms TRKA G595R, TRKA G667C, and TRKA F589L,</p>Formule :C39H45N7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :659.82VEGFR-2-IN-37
CAS :<p>VEGFR-2-IN-37 (compound 12), a VEGFR-2 inhibitor, exhibits an inhibition rate of approximately 56.9 μM at a concentration of 200 μM.</p>Formule :C18H16N2O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :324.4BT424
CAS :BT424, a specific HCK inhibitor, modulates macrophage activation and autophagy in vitro, and mitigates inflammation and renal fibrosis in the UUO model [1].Formule :C22H15BCl2N2O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :421.08Cinsebrutinib
CAS :<p>Cinsebrutinib, a Bruton's tyrosine kinase inhibitor, holds potential for research in cancer treatment.</p>Formule :C22H26FN3O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :383.46FGFR3-IN-7
CAS :<p>FGFR3-IN-7 is a potent, selective inhibitor of FGFR 3, demonstrating an IC50 value of less than 350 nM , and is utilized in cancer research [1].</p>Formule :C25H24FN9ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :485.52Resigratinib
CAS :<p>Resigratinib (KIN-3248) is an oral, irreversible pan-FGFR family protein inhibitor, covalently binds to and inhibits all four FGFR isoforms(FGFR1/2/3/4).</p>Formule :C26H27F2N7O3Degré de pureté :98.58%Couleur et forme :SolidMasse moléculaire :523.53Terevalefim
CAS :<p>Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.</p>Formule :C9H8N2SDegré de pureté :99.8%Couleur et forme :SolidMasse moléculaire :176.24VEGFR2-IN-3
CAS :<p>VEGFR2-IN-3 (compound 385) is a potent inhibitor of VEGFR2 [1].</p>Formule :C26H28ClN5O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :509.98ARRY-382
CAS :<p>ARRY-382 is a highly selective oral inhibitor of CSF-1R with an IC50 of 9 nM.</p>Formule :C32H36N8O2Degré de pureté :99.76%Couleur et forme :SolidMasse moléculaire :564.68Lifirafenib
CAS :<p>Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant</p>Formule :C25H17F3N4O3Degré de pureté :98% - 98.25%Couleur et forme :SolidMasse moléculaire :478.42VEGFR-2-IN-9
CAS :<p>VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor (IC50: 7 nM). It can be used to study breast cancer.</p>Formule :C23H25N3O3Degré de pureté :97.19%Couleur et forme :SolidMasse moléculaire :391.46TIE-2/VEGFR-2 kinase-IN-5
CAS :<p>TIE-2/VEGFR-2 kinase-IN-5 is a TIE-2 and VEGFR-2 tyrosine kinase receptor inhibitor commonly used in biomedical research related to angiogenesis.</p>Formule :C21H13F6N5O2Degré de pureté :99.79%Couleur et forme :SolidMasse moléculaire :481.35Simotinib
CAS :<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Formule :C25H26ClFN4O4Degré de pureté :99.7%Couleur et forme :SolidMasse moléculaire :500.95EGFR mutant-IN-1
<p>EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.</p>Formule :C34H39ClFN7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :632.17PF-06733804
CAS :<p>PF-06733804 is a potent inhibitor of pan-Trk in cell-based assays (IC50s: 8.4 nM, 6.2 nM, and 2.2 nM for TrkA, TrkB, and TrkC) with anti-hyperalgesic effect.</p>Formule :C20H19F5N4O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :474.38PAT-505
CAS :<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Formule :C23H18ClF2N3O2SDegré de pureté :98.84%Couleur et forme :SolidMasse moléculaire :473.92CG 428
CAS :<p>CG 428 is a potent tropomyosin receptor Kinase (TRK) Degrader (uSMITETM) with a DC50 of 0.36 nM.</p>Formule :C43H43FN10O6Degré de pureté :99.83%Couleur et forme :SolidMasse moléculaire :814.86Edralbrutinib
CAS :<p>Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood and</p>Formule :C26H21F2N5O3Degré de pureté :99.41%Couleur et forme :SolidMasse moléculaire :489.47TYRA-300
CAS :<p>TYRA-300 is an oral and selective FGFR3 inhibito, in the Ba/F3 cell line for the treatment of metastatic uroepithelial carcinomas (mUCs) and chondrodysplasia.</p>Formule :C25H24Cl2N6O3SDegré de pureté :99.66%Couleur et forme :SolidMasse moléculaire :559.47DYRKs-IN-2
CAS :<p>DYRKs-IN-2 has antitumor activity. DYRKs-IN-2 is a potent DYRKs inhibitor with IC50s of 30.6 nM and 12.8 nM for DYRK1B and DYRK1A, respectively.</p>Formule :C32H38ClN9O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :632.16c-met-IN-1
CAS :<p>c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.</p>Formule :C35H37FN6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :640.7HKI-357
CAS :<p>HKI-357 irreversibly inhibits EGFR/ERBB2 (IC50: 34/33 nM), blocks EGFR Y1068 autophosphorylation, and AKT/MAPK phosphorylation.</p>Formule :C31H29ClFN5O3Degré de pureté :99.91%Couleur et forme :SolidMasse moléculaire :574.05BMX-IN-1
CAS :<p>BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosine</p>Formule :C29H24N4O4SDegré de pureté :98.38%Couleur et forme :SolidMasse moléculaire :524.59PF-06250112
CAS :<p>PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM.</p>Formule :C22H20F2N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :438.43BMS-599626 Hydrochloride
CAS :<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Formule :C27H28ClFN8O3Degré de pureté :99.98%Couleur et forme :SolidMasse moléculaire :567.01ALK-IN-27
CAS :<p>Neladalkib (NVL-655) is an ALK inhibitor with antitumor activity for the study of non-small cell cancers.</p>Formule :C23H22ClFN6ODegré de pureté :99.71%Couleur et forme :SolidMasse moléculaire :452.91FIIN-1
CAS :<p>FIIN-1 (FGFR irreversible inhibitor-1) is an irreversible and selective FGFR inhibitor with Kd of 2.8, 6.9, 5.4, 120, 32 and 120 nM for FGFR1, FGFR2, FGFR3,</p>Formule :C32H39Cl2N7O4Degré de pureté :98.75%Couleur et forme :SolidMasse moléculaire :656.6EGFR-IN-1 hydrochloride
CAS :<p>EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.</p>Formule :C28H31ClN6O4Degré de pureté :99.16%Couleur et forme :SolidMasse moléculaire :551.04TAK-020
CAS :<p>TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.</p>Formule :C18H17N5O3Degré de pureté :98.79%Couleur et forme :SolidMasse moléculaire :351.36BGB-8035
CAS :<p>BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.</p>Formule :C24H31N5O4Degré de pureté :96.74%Couleur et forme :SolidMasse moléculaire :453.53WAY-600
CAS :<p>WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) but not P-AKT(T308).</p>Formule :C28H30N8ODegré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :494.59Tyrphostin AG 538
CAS :<p>Tyrphostin AG 538 is a chalcone compound, an IGF-1 receptor kinase inhibitor (IC₅0 : for 400 nM) that is potent, cell-permeable, reversible, and competitive.</p>Formule :C16H11NO5Degré de pureté :98.75%Couleur et forme :SoildMasse moléculaire :297.26MK-2461
CAS :<p>MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an</p>Formule :C24H25N5O5SDegré de pureté :95.41% - 99.53%Couleur et forme :SolidMasse moléculaire :495.55Ropsacitinib
CAS :<p>Ropsacitinib (PF-06826647) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain (IC50: 17 nM).</p>Formule :C20H17N9Degré de pureté :99.87%Couleur et forme :SolidMasse moléculaire :383.41BTK inhibitor 1
CAS :<p>BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.</p>Formule :C24H23FN8O2Degré de pureté :98.24% - 98.91%Couleur et forme :SolidMasse moléculaire :474.49Zidesamtinib
CAS :<p>Zidesamtinib (NVL-520) is a ROS1 fusion and resistance mutation inhibitor that inhibits ROS1 and can be used to study non-small cell lung cancer.</p>Formule :C22H22FN7ODegré de pureté :99.74%Couleur et forme :SolidMasse moléculaire :419.455CH6953755
CAS :<p>CH6953755: oral YES1 kinase inhibitor, IC50 1.8 nM, potent, selective, anticancer, halts cell proliferation.</p>Formule :C26H22F2N6O4SDegré de pureté :98.03%Couleur et forme :SolidMasse moléculaire :552.55EGFR/ErbB-2 inhibitor-1
CAS :<p>EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.</p>Formule :C23H15ClFN3OS2Degré de pureté :98.93%Couleur et forme :SolidMasse moléculaire :467.97EGFR-IN-87
CAS :EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Formule :C28H33N7O2Degré de pureté :98.64%Couleur et forme :SolidMasse moléculaire :499.61Sevabertinib
CAS :<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Formule :C24H25ClN4O5Degré de pureté :99.81%Couleur et forme :SolidMasse moléculaire :484.93Src Inhibitor 3
CAS :<p>Src Inhibitor 3 blocks c-Src kinase (IC50 <3 nM CSK HTRF, <4 nM Caliper), boosting T cell growth from receptor signals.</p>Formule :C34H32ClFN8O4Degré de pureté :98.35%Couleur et forme :SolidMasse moléculaire :671.12AZ-23
CAS :<p>AZ-23 is an inhibitor of ATP-competitive and Trk kinase A/B/C.</p>Formule :C17H19ClFN7ODegré de pureté :99.4%Couleur et forme :SolidMasse moléculaire :391.83EGFR-IN-8
CAS :<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Formule :C32H23ClF3N7O4Degré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :662.02HER2-IN-21
CAS :<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Formule :C20H18N4O3SCouleur et forme :SolidMasse moléculaire :394.447Tyrphostin 63
CAS :<p>Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.</p>Formule :C10H8N2OCouleur et forme :SolidMasse moléculaire :172.183Tarloxotinib bromide
CAS :Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.Formule :C24H24Br2ClN9O3Degré de pureté :99.52%Couleur et forme :SolidMasse moléculaire :681.77TrkA-IN-9
CAS :<p>TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.</p>Formule :C31H32N4O4Couleur et forme :SolidMasse moléculaire :524.61FMP-API-1
CAS :<p>FMP-API-1 is an inhibitor of the A-kinase anchoring protein (AKAP)-PKA interaction. It binds to the allosteric site of the PKAR subunit, enhancing the activity of PKA and AQP2 in PKA knockout cell lines of the renal cortex collecting duct (mpkCCD cells). FMP-API-1 holds potential for studying nephrogenic diabetes insipidus (NDI).</p>Formule :C13H14N2O2Couleur et forme :SolidMasse moléculaire :230.262DDR1-IN-8
CAS :<p>DDR1-IN-8 (compound 7s) is a potent inhibitor of DDR1/2, exhibiting IC50 values of 0.045 μM and 0.126 μM, respectively, and possesses antitumor activity.</p>Formule :C23H24F3N5O2Masse moléculaire :459.46TrkC-IN-1
CAS :<p>TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.</p>Formule :C28H20BrN5O2Couleur et forme :SolidMasse moléculaire :538.395TrkA-IN-8
CAS :<p>TrkA-IN-8 (Compound 2) is a TrkA inhibitor with a Kd value of 3.3 µM. RTKs-IN-1 demonstrates a concentration-dependent inhibitory effect on the proliferation of lung cancer cell lines and holds potential for research in non-small cell lung cancer.</p>Formule :C20H16N4Couleur et forme :SolidMasse moléculaire :312.368IGF-1R inhibitor-4
CAS :<p>IGF-1Rinhibitor-4 (compound 22) is a potent inhibitor of IGF-1R, demonstrating an inhibition rate of 63% at a concentration of 10 μM. This compound plays a significant role in cancer research.</p>Formule :C13H15ClN4OCouleur et forme :SolidMasse moléculaire :278.737Andamertinib
CAS :<p>Andamertinib is an EGFR inhibitor with antitumor activity.</p>Formule :C31H36N8O3Couleur et forme :SolidMasse moléculaire :568.669FGFR4-IN-4
CAS :<p>FGFR4-IN-4 is a FGFR4 inhibitor with anti-tumor activity.</p>Formule :C28H32Cl2N6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :603.5EGFR-IN-139
CAS :<p>EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).</p>Formule :C27H25ClN2O4Couleur et forme :SolidMasse moléculaire :476.951GENZ-882706
CAS :<p>GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor.</p>Formule :C26H25N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :455.51ITK inhibitor 2
CAS :<p>ITK inhibitor 2 (compound 4) is a potent and selective ITK inhibitor with an IC50= 2 nM.</p>Formule :C25H33N5O2Degré de pureté :99.67%Couleur et forme :SolidMasse moléculaire :435.56Pimicotinib hydrochloride
CAS :<p>Pimicotinib hydrochloride is an inhibitor of CSF1R, displaying antitumor activity.</p>Formule :C22H25ClN6O3Couleur et forme :SolidMasse moléculaire :456.925DYR530
CAS :<p>DYR530 is a ligand for the target protein (protein kinase DYRK1A) of PROTAC.</p>Formule :C23H24FN7Couleur et forme :SolidMasse moléculaire :417.48CGP062464
CAS :<p>CGP062464 is an inhibitor of the tyrosine kinase c-Src, with an IC50 of less than 50 nM. It is utilized in research related to osteoporosis and tumor-induced hypercalcemia.</p>Formule :C18H14N4Couleur et forme :SolidMasse moléculaire :286.331NS-062
CAS :<p>NS-062 is an orally effective, irreversible covalent inhibitor targeting EGFR, demonstrating antiproliferative activity in the resistant double mutant H1975 cells with an IC50 of 0.19 μM. It also exhibits antitumor activity in a murine H1975 xenograft model.</p>Formule :C28H30Cl2F2N6O4Couleur et forme :SolidMasse moléculaire :623.48Enrupatinib
CAS :<p>Enrupatinib is an inhibitor of the colony stimulating factor 1 receptor (CSF1R), exhibiting antitumor activity.</p>Formule :C27H26N6O3Couleur et forme :SolidMasse moléculaire :482.53EGFR-IN-149
CAS :<p>EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.</p>Formule :C16H15N3OSCouleur et forme :SolidMasse moléculaire :297.375EGFR-IN-130
<p>EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.</p>Formule :C27H25N3O6SCouleur et forme :SolidMasse moléculaire :519.57c-Met-IN-26
CAS :c-Met-IN-26 (compound 1-170) is an effective inhibitor of c-Met, exhibiting an IC50 of 1.6 nM.Formule :C24H19F2N9Couleur et forme :SolidMasse moléculaire :471.46Fanregratinib
CAS :Fanregratinib is a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.Formule :C27H33ClN6O2Couleur et forme :SolidMasse moléculaire :509.04HER2-IN-9
<p>HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.</p>Formule :C19H14BrF3N2OCouleur et forme :SolidMasse moléculaire :423.23FGFR-IN-16
CAS :<p>FGFR-IN-16 (compound 7N) is a potent inhibitor of FGFR1, FGFR2, and FGFR4, exhibiting IC50 values of 8 nM, 4 nM, and 3.8 nM respectively. It plays a crucial role in cancer research.</p>Formule :C30H27Cl2N7O4Couleur et forme :SolidMasse moléculaire :620.49WS-11
CAS :<p>WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.</p>Formule :C26H22FN9O2Couleur et forme :SolidMasse moléculaire :511.51BML-265
CAS :<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Formule :C18H15N3O2Couleur et forme :SolidMasse moléculaire :305.331FGFR-IN-15
<p>FGFR-IN-15 (compound 18i) acts as a pan-FGFR inhibitor, exhibiting potent inhibitory activity against FGFR1-4.</p>Formule :C22H23N5O5SCouleur et forme :SolidMasse moléculaire :469.51c-Met-IN-2
CAS :<p>c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.</p>Formule :C24H21FN10ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :484.49MerTK-IN-1
CAS :<p>MerTK-IN-1 (compound 31) serves as an inhibitor of MerTK, with the capability to bind to the target in vivo.</p>Formule :C23H26N8O4Couleur et forme :SolidMasse moléculaire :478.50Dyrk1A-IN-11
CAS :<p>Dyrk1A-IN-11 (compound 166) is an effective inhibitor targeting dual-specificity tyrosine phosphorylation-regulated 1A (DYRK1A) with an EC50 of 0.0021 µM. Additionally, this compound inhibits the phosphorylation of Tau (Thr212) with an EC50 of 0.0361 µM.</p>Formule :C23H23F5N8OCouleur et forme :SolidMasse moléculaire :522.47Tesevatinib tosylate
CAS :<p>Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.</p>Formule :C31H33Cl2FN4O5SCouleur et forme :SolidMasse moléculaire :663.59EGFR/BRAF-IN-1
<p>EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.</p>Formule :C26H28ClN3O4Couleur et forme :SolidMasse moléculaire :481.97EGFR-IN-125
CAS :<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Formule :C30H26N8OCouleur et forme :SolidMasse moléculaire :514.58EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Formule :C31H30FN7OCouleur et forme :SolidMasse moléculaire :535.61HER2-IN-7
CAS :<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Formule :C28H26F3N7O3Couleur et forme :SolidMasse moléculaire :565.55EG31
CAS :<p>EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.</p>Formule :C30H13Br2N3O6Couleur et forme :SolidMasse moléculaire :671.25EGFR-IN-160
CAS :EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formule :C15H12N2O4Couleur et forme :SolidMasse moléculaire :284.27G-744
CAS :<p>G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM).</p>Formule :C29H29N5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :527.64EGFR/HER2-IN-5
<p>EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.</p>Couleur et forme :SolidProtein kinase inhibitor 4
CAS :<p>Protein kinase inhibitor 4 (Compound 3) is a chemical that acts as a protein kinase inhibitor, specifically targeting TRK-A with an IC50 of 3.0 nM, and ROS1 with an IC50 of 104 nM.</p>Formule :C25H24F2N6O3SMasse moléculaire :526.56c-Fms-IN-15
CAS :<p>c-Fms-IN-15 (compound 8g) is a potent inhibitor of FMS kinase, with an IC50 of 563 nM.</p>Formule :C29H28F3N7O2Masse moléculaire :563.57LSD1/EGFR-IN-1
CAS :<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Formule :C21H20ClN3O4Couleur et forme :SolidMasse moléculaire :413.854EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Couleur et forme :SolidEGFR-IN-133
CAS :<p>EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.</p>Formule :C27H29F2N7O3Couleur et forme :SolidMasse moléculaire :537.56PF-06273340
CAS :<p>PF-06273340 是一种口服具有活力的、具有选择性的外周限制性Trk 泛抑制剂。</p>Formule :C23H22ClN7O3Degré de pureté :98% - 98.00%Couleur et forme :SolidMasse moléculaire :479.92UniPR500
CAS :<p>UniPR500, a derivative of UniPR129, is a competitive antagonist for the EphA2 receptor, with a Ki of 0.78 μM. It reduces the binding of biotinylated Ephrin-A1 to EphA2 in a dose-dependent manner, exhibiting an IC50 value of 1.1 μM.</p>Formule :C36H51N3O4Couleur et forme :SolidMasse moléculaire :589.808VEGFR2-IN-1
CAS :<p>VEGFR2-IN-1 is a VEGFR2 inhibitor with antitumor activity used in the study of breast cancer.</p>Formule :C22H18N6SDegré de pureté :98.15%Couleur et forme :SolidMasse moléculaire :398.48EGFR-IN-147
CAS :<p>EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.</p>Formule :C13H13N5OCouleur et forme :SolidMasse moléculaire :255.275EGFR-IN-132
CAS :<p>EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.</p>Formule :C27H31N7O3Couleur et forme :SolidMasse moléculaire :501.58AMG-25
CAS :<p>AMG-25 (c-Kit-IN-5-1) is a c-Kit inhibitor that inhibits c-Kit, KDR, p38, Lck, and Src, and can be used for the study of mast cell-associated fibrotic diseases.</p>Formule :C23H17N5O2Degré de pureté :98.16%Couleur et forme :SolidMasse moléculaire :395.41EGFR/HER2-IN-7
<p>EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.</p>Formule :C19H21N3O2SCouleur et forme :SolidMasse moléculaire :355.45NSC381467
CAS :<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formule :C20H16O7Couleur et forme :SolidMasse moléculaire :368.34DDR1-IN-10
CAS :<p>DDR1-IN-10 (compound 7q) is an inhibitor of DDR1. It is applicable in research related to pancreatic cancer, non-small cell lung cancer, and gastric cancer.</p>Formule :C24H25F4N5O2Couleur et forme :SolidMasse moléculaire :491.481DDR1/2 inhibitor-3
CAS :<p>DDR1/2 inhibitor-3 (5n) is an inhibitor of DDR1/2, with IC50 values of 9.4 nM and 20.4 nM, respectively. It is applicable in anti-inflammatory research.</p>Formule :C31H31F3N6OCouleur et forme :SolidMasse moléculaire :560.613JBJ-09-063
CAS :<p>JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.</p>Formule :C31H29FN4O3SCouleur et forme :SolidMasse moléculaire :556.65ONO-7579
CAS :<p>ONO-7579, an orally active TRKA inhibitor, effectively suppresses tumor growth by inhibiting TRKA phosphorylation. In KM12 colorectal cancer cells, it exhibits an EC 50 of 17.6 ng/g, indicating that a concentration of 17.6 ng per gram of tumor tissue reduces the activity of phosphorylated TRKA by 50%. This compound is utilized in cancer research.</p>Formule :C24H18ClF3N6O4SCouleur et forme :SolidMasse moléculaire :578.95
